Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY24 results · Apr–Jun 2023
Eris Lifesciences reported revenue from operations of ₹466.62 crore (up 17.1% from Q1 FY23) and net profit of ₹93.65 crore (up 0.6% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 466.62 | 398.58 | +17.1% | 402.80 | +15.8% |
| Other income | 0.99 | 2.74 | −63.9% | 1.00 | −1.5% |
| Total income | 467.61 | 401.32 | +16.5% | 403.80 | +15.8% |
| Profit before tax | 112.48 | 101.27 | +11.1% | 75.90 | +48.2% |
| Net profit for the period | 93.65 | 93.08 | +0.6% | 61.48 | +52.3% |
| Attributable to shareholders of the company | 94.86 | 94.58 | +0.3% | 65.42 | +45.0% |
| EPS, basic (₹) | 6.97 | 6.96 | +0.1% | 4.81 | +44.9% |
| Net margin (%) | 20.1 | 23.4 | 15.3 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 411.29 | 328.76 | +25.1% | 314.58 | +30.7% |
| Other income | 4.03 | 3.37 | +19.4% | 4.26 | −5.5% |
| Total income | 415.31 | 332.13 | +25.0% | 318.84 | +30.3% |
| Profit before tax | 132.52 | 107.36 | +23.4% | 95.51 | +38.8% |
| Net profit for the period | 110.74 | 95.59 | +15.8% | 87.84 | +26.1% |
| EPS, basic (₹) | 8.14 | 7.03 | +15.8% | 6.46 | +26.0% |
| Net margin (%) | 26.9 | 29.1 | 27.9 |
Consolidated
- Filed with BSE
- 07 Aug 2023, 17:58 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2023, 17:58 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE